Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson’s disease; plan to initiate RESTORE-2 trial in […]